Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for RBC Bioscience's Days Payable or its related term are showing as below:
During the past 9 years, RBC Bioscience's highest Days Payable was 89.72. The lowest was 59.14. And the median was 74.43.
ROCO:6848's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 112.84 * Ranked among companies with meaningful Days Payable only.
RBC Bioscience's Days Payable
stayed the same
from Dec. 2024 (0.00) to Dec. 2025 (0.00).
RBC Bioscience Days Payable Related Terms
RBC Bioscience Days Payable Historical Data
* Premium members only.
The historical data trend for RBC Bioscience's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6848 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, RBC Bioscience's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RBC Bioscience Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RBC Bioscience's Days Payable distribution charts can be found below:
* The bar in red indicates where RBC Bioscience's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
RBC Bioscience's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RBC Bioscience (ROCO:6848) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on RBC Bioscience and its competitors. Over the past decade, RBC Bioscience's Days Payable has ranged from 59.14 to 89.72. According to the industry distribution chart, RBC Bioscience ranks #999999 out of 701 companies in the Biotechnology industry.
Is RBC Bioscience's Days Payable too high?
RBC Bioscience's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 59.14 to a high of 89.72. Based on the distribution chart, RBC Bioscience ranks #999999 out of 701 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, RBC Bioscience has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does RBC Bioscience's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RBC Bioscience ranks #999999 out of 701 companies for Days Payable. This places RBC Bioscience in the lower half of its industry. The industry median Days Payable is 112.84. Historically, RBC Bioscience's own Days Payable has ranged from 59.14 to 89.72 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on RBC Bioscience and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RBC Bioscience's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RBC Bioscience stock overvalued right now?
Based on GuruFocus' analysis, RBC Bioscience (ROCO:6848) is currently considered Fairly Valued. The stock's GF Value™ is NT$19.91, compared to a current price of NT$20.50 — trading 3% above its estimated fair value. The current Days Payable is 0.00. RBC Bioscience's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For RBC Bioscience (ROCO:6848), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RBC Bioscience (ROCO:6848) Overvalued in 2026?
Based on GuruFocus' analysis, RBC Bioscience stock appears to be overvalued.
The current stock price of NT$20.50 is trading 3% above its estimated GF Value™ of NT$19.91.
GuruFocus considers RBC Bioscience to be Fairly Valued.
Key valuation signals for ROCO:6848:
Days Payable: 0.00
GF Value™: NT$19.91 vs. price of NT$20.50 (3% above fair value)
No single metric tells the full story. See the ROCO:6848 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RBC Bioscience Corp is a bio-sciences company. Its products include the manufacture and sale of molecular biological medical diagnosis and research reagents, gene extraction automatic testing instruments, and gene extraction reagent tissues.
76GF Score
Get the complete analysis for ROCO:6848
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6848 has been successfully added to your 
